211871-56-6

Basic information

• Product Name: Acetamide, N-[1,1-dimethyl-2-(2-naphthalenyl)ethyl]-
• Synonyms: Acetamide, N-[1,1-dimethyl-2-(2-naphthalenyl)ethyl]-
• CAS NO: 211871-56-6
• Molecular Formula: C16H19NO
• Molecular Weight: 241
• Mol File: 211871-56-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Acetamide, N-[1,1-dimethyl-2-(2-naphthalenyl)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[1,1-dimethyl-2-(2-naphthalenyl)ethyl]-(211871-56-6)
• EPA Substance Registry System: Acetamide, N-[1,1-dimethyl-2-(2-naphthalenyl)ethyl]-(211871-56-6)

Safety Data

• Hazardous Substances Data: 211871-56-6(Hazardous Substances Data)

Upstream product

• 198226-63-0 [2-methyl-1-(naphthalen-2-yl)propan-2-yl]amine 
• 108-24-7 acetic anhydride 
• 72040-90-5 2-(2-methylprop-1-en-1-yl)naphthalene 
• 66-99-9 β-naphthaldehyde 
• 87077-99-4 2-methyl-3-(β-naphthyl)propan-2-ol 
• 64-19-7 acetic acid 
• 75-05-8 acetonitrile 

Relevant articles and documents

Calcium receptor antagonist

A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

CALCIUM RECEPTOR ANTAGONISTS

wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

Photoamination of Alkenylnaphthalenes with Ammonia via Electron Transfer

The photoamination of l-(2-methyl-l-propenyl)naphthalene (1a) with ammonia in the presence of p-dicyanobenzene (p-DCB) occurred selectively at the alkenyl group but not at the naphthyl group to give l-(2-amino-2-methylpropyl)naphthalene (2a). Similarly, the photoamination of several kinds of alkenylnaphthalenes (1) proceeded selectively at the alkenyl group. The photoamination proceeded via the nucleophilic addition of ammonia to the cation radical of 1 generated by the photoinduced electron transfer to p-DCB to give the aminated radical after deprotonation. Distribution of the positive charge in 1+· and the stabilities of the aminated radicals were calculated by the PM3-UHF method. The stabilities of the aminated radicals agreed with the regioselectivity.